Ara 290 vs Thymosin Beta-4
Extensively Studied vs Well Studied
compatible No known interactions; different mechanisms for tissue protection.
Molecular Data
Ara 290 Thymosin Beta-4
Weight 1,257 Da 4,963.44 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) Dose-dependent; relatively short (exact values not established)
Chain 11 amino acids 43 amino acids
Type Engineered peptide Thymosin peptide
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
Thymosin Beta-4
01 Systemic regenerative effects
02 Proven clinical efficacy
03 Optimal bioavailability for tissue repair
04 Promotes angiogenesis
05 Reduces inflammation
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
Thymosin Beta-4
2-6mg per injection (varies by protocol and severity) / Daily for acute healing, 2x weekly for maintenance/chronic conditions
Acute Wound Healing 1.6mg Daily
Cardiac Protection 42mg Single dose
Chronic Tissue Repair 6mg Twice weekly
Neurological Recovery 30mg Three times over 72 hours
General Regeneration 2-5mg Daily or every other day
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
Thymosin Beta-4
Mild injection site reactions
Local inflammation at injection sites
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Active chemotherapy treatment
Severe systemic allergies to peptides
Research Evidence
Ara 290 Thymosin Beta-4
Status Extensively Studied Well Studied
References 5 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.